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Abstract
Myocoptes musculinus is the most common fur mite identified among laboratory mice; infested mice, in addition 
to dermatological signs, may also be prone to secondary infections, affecting the outcome of a research trial. This trial 
was conducted in order to assess the safety and efficacy of a single topical administration of eprinomectin (5mg/kg 
BW) in a naturally infested laboratory mice colony. A safety trial was conducted on 20 uninfested pregnant females 
assigned to two groups, receiving eprinomectin and mineral oil, respectively. The mice were examined daily for signs of 
illness or toxicity; nests were individually weighted at 21 and 28 days postpartum. No acute toxicity was observed, all 
treated females gave full term delivery and number and mean weight of newborns ranged in the physiological values. To 
evaluate the efficacy, 20 naturally infested non-pregnant females were divided into two groups, treated as in the safety 
trial. Animals were observed daily for 15 min until 21 days post-treatment (DPT) and a “pruritus index” (PI: scratching 
and gnawing acts/mouse/min) was calculated. Pelage examination was performed on DPT 7, 14, 21 and 50. The 
“PI” was significantly lower in the treated group and mites were eradicated from all infested animals. A single topical 
administration of eprinomectin at a (high) dosage of 5mg/kg BW was safe and effective to control M. musculinus in 
mice.
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Resumo
Myocoptes musculinus é o ácaro de pele mais comum identificado entre camundongos de laboratório. Camundongos 
infestados, além de sinais dermatológicos, também podem ser propensos a infecções secundárias, interferindo 
no resultado de um ensaio de pesquisa. Este estudo foi realizado para avaliar a segurança e eficácia de uma única 
administração tópica de eprinomectina (5mg / kg PV) em uma colônia de camundongos de laboratório naturalmente 
infestada. Um estudo de segurança foi realizado em 20 fêmeas prenhes sadias, divididas em dois grupos, recebendo 
eprinomectina e óleo mineral, respectivamente. Os camundongos foram examinados diariamente para detectar 
quaisquer sinais da doença ou toxicidade; camundongos recém-nascidos foram pesados individualmente aos 21 e 28 dias 
pós-parto. Nenhuma toxicidade aguda foi observada. Todas as fêmeas tratadas chegaram ao parto, o número e peso 
dos recém-nascidos variaram dentro de parâmetros fisiológicos. Para avaliar a eficácia, 20 camundongos não prenhes, 
naturalmente infestados, foram divididos em dois grupos: tratado e grupo controle não tratado. Os animais foram 
observados diariamente durante 15 minutos até os 21 dias pós- tratamento (DPT) e um índice de prurido (IP) - 
arranhões e ato de roer / camundongo / min) foi calculado. Exame da pelagem foi realizado em DPT 7, 14, 21 e 50. O 
IP foi significativamente menor no grupo tratado, e os ácaros foram erradicados de todos os animais infestados. Uma 
única administração tópica de eprinomectina, na dose de 5mg / kg de peso corporal, foi segura e eficaz no controle de 
M. musculinus em camundongos.
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Eprinomectin in mice
Myocoptes musculinus is the most common fur mite identified 
among laboratory mice (FOX et al., 2002) and it has been associated 
with excessive pruritus; alopecia and a range of conditions, including 
ulcerative dermatitis, hypersensitivity dermatitis, and pyoderma 
can also develop (FOX et al., 2002, 2007). Infested mice may also 
be prone to secondary infections, reduced life span, and decrease 
of body weight (WELTER et al., 2007).
A number of published studies have reported successful colony 
eradication of fur mites with oral ivermectin (CONOLE et al., 
2003; RICART ARBONA et  al., 2010), oral moxidectin 
(POLLICINO et al., 2008), injectable ivermectin (WING et al., 
1985) and topical parasiticides as selamectin (GONENC et al., 2006; 
MOOK; BENJAMIN, 2008), ivermectin (BAUMANS et al., 1988; 
MOOK; BENJAMIN, 2008) and moxidectin (PULLIUM et al., 
2005; MOOK; BENJAMIN, 2008).
Here we reported the effectiveness and safety of a single topical 
administration of eprinomectin to control Myocoptes musculinus 
infestation in a naturally infested laboratory mice colony.
In January 2012, mice exhibiting excessive pruritus as the 
only clinical sign were signaled at a laboratory animal facility of 
the University of Turin, Italy.
The laboratory animal facility housed approximately 2700 adult 
male and female conventional and transgenic mice (FVB/NCrl, 
C57, BalbC/a and 129/OLA).
The animal facility, including the environmental conditions 
(12-h light: 12-h dark cycle, RT 21 °C ± 1 °C and RH 55% ±5%) 
and animal housing were within the requirements established 
by European and National laws (86/609/CEE and DL 116/92). 
Animals housed in same-sex groups of 10 in transparent conventional 
polycarbonate cages (Tecnoplast, Buggirate, Italy) with isolator 
tops and corncob bedding, were fed rodent chow (4RF18GLP 
Rodent Diet, Mucedola Srl, Settimo Milanese, Italy) and provided 
with tap water ad libitum. Fur samples were obtained from 50 
symptomatic animals, randomly selected in 50 different cages.
For pelage test, a 2×8 cm of clear scotch tape (Scotch® Crystal, 
3Mtm, Milan, Italy ) was thoroughly rubbed on the head, neck, 
back, ventral region of the thorax and abdomen of each mouse. 
The tape was then affixed to a glass microscope slide with a drop 
of oil and examined for ectoparasites at 40x magnification.
A pelage sample was also cultured on Mycobios-selective 
agar (Biolife Italiana Srl, Milan, Italy) to exclude concomitant 
dermatophytosis as the cause of the dermatological lesions.
Pelage examination revealed Myocoptes musculinus adult fur 
mites and/or larvae and/or eggs in all the 50 mice examined. No 
other ectoparasites were detected, and all cultures were negative 
for dermatophytes.
Since the lifecycle of M. musculinus ranges from 8 to 14 days, 
with eggs hatching in 5 days (FOX et al., 2002), and because of 
its surface-feeding nature, in the effort to develop a simple and 
rapid one-time treatment protocol, a single topical administration 
of eprinomectin was tested.
A preliminary safety trial was conducted on 20 FVB/NCrl 
uninfested pregnant females (term delivery at 24 h-10 days); 
animals were isolated in individual cages and randomly assigned to 
one of two experimental groups of 10. Group A received pour-on 
eprinomectin (Eprinex® Pour-on, Merial Italia SpA, containing 
0.5% active ingredient) at the approximate dosage of 5 mg/kg 
BW (27µL/mouse). Eprinex® Pour-on was topically applied to 
the skin in a single spot at the base of the neck. Control mice 
(Group B) received 27µL mineral oil on the same day. Mice 
were examined daily for any signs of illness or toxicity, including 
neurological abnormalities; moreover, to monitor the growth, 
nests were individually weighted at 21 and 28 days post partum.
No acute toxicity was observed in 10 treated mothers, and gross 
behavior and appetite were not affected. All treated females gave 
full term delivery and number of newborns ranged from 4 to 7, for 
a total of 58 mice. The mean weight of newborns was 10.8+0.3 g 
at the age of 3 weeks, and 16.1+0.4 g at the age of 4 weeks, ranging 
in the physiological values of the corresponding line (Charles River 
Laboratories, 2004). No statistical differences were recorded in 
controlled mice, regarding the number of newborns (a total of 
60, ranging from 4 to 8) and the mean weight 11.5 grams+0.5 g 
at the age of 3 weeks and 16.8 grams+0.3 g at 4 weeks.
In parallel, an efficacy trial was carried out on 20 naturally 
infested non-pregnant females, which were divided into 
Groups C and D, based on detection of fur mites and/or their 
eggs. A third group (Group E) of 10 uninfested mice served 
as untreated control. On Day 0, Group C received pour-on 
eprinomectin (same formulation, application and dosage as in the 
safety trial); positive control mice (Group D) and uninfested mice 
(Group E) received 27µL mineral oil on the same day. Each group 
was observed daily for 15 min, during the 3 days of pre-treatment 
up to 21 days post-treatment; observation involved evaluation 
of clinical signs of infestation such as scratching, alopecia, rough 
coat, presence of scabs or sores, and trauma to ears or skin or no 
outward clinical signs of infestation.
All scratching and gnawing acts were recorded and a “pruritus 
index” (acts/mouse/min) was calculated, according to Jensen et al. 
(2002) and Loewenstein et al. (2006). The presence/absence 
of mites and/or their eggs was estimated in all mice within 
Groups C and D by double (ventral and dorsal) pelage tape test 
on experimental days 7, 14, 21 and 50. Numbers of scratching 
and gnawing acts recorded in Groups C and D were compared 
by the Student’s t-test.
No side effects or signs of illness were observed in any of the 
treated animals. Treatment resulted in clinical improvement after 
the first week following Eprinex® Pour-on administration. After 
the first day of post-treatment a significant decrease (P≤0.001) 
of scratching and gnawing acts was recorded (Figure 1). On day 
7 pelage tape tests showed that all mites were eliminated; only 
empty and unviable desiccated eggs (Figure 2) were observed in 
the treated group on days 7, 14 and 21 (in 70%, 90% and 20% 
of mice, respectively), and no egg or mite on day 50.
Positive control mice showed no clinical improvement compared 
to the treated group, the “pruritus index” was significantly (from 
P≤0.01 to ≤0.001) higher in all three experimental weeks.
At the end of the trial positive control mice were treated.
Fur mites infestations in research colonies remain a constant 
management challenge. Fur mites have been reported to interfere 
with established research models by directly potentiating allergic-
type hypersensitivity reactions (MORITA et al., 1999), indirectly 
interfering with normal immune responses to other (WELTER et al., 
2007) and have been shown to provoke a Th2 immune response 
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and elevate serum IgE (LALTOO et al., 1979; JUNGMANN et al., 
1996).
In spite of the labor and time saving of oral administration in 
drinking water or food, a widespread acaricide treatment could 
be contraindicated due to the potential for adverse effects; for 
example, ivermectin and moxidectin, although effective against 
fur mites, can be lethal in neonatal pups and genetically modified 
mice with defective blood-brain barriers (SCHINKEL et al., 1994; 
SKOPETS et al., 1996); moreover, moxidectin was also associated 
to an episode of acute toxicosis and mortality after routine 
prophylactic treatment in two strains of mice (LEE et al., 2009).
Topical administration, even if it requires a more intensive 
labor, ensures accurate dosing of the single mouse and prevents 
inadvertent toxicosis.
Under the conditions of this study, the tested single-dosage 
had similar efficacy as the single-dosage topical treatment with 
moxidectin, which is a well recognized operator-friendly option 
for control and eradication of the fur mite in large colonies of 
laboratory mice.
A single topical administration of eprinomectin at a high 
dosage of 5 mg/kg BW was safe and effective in the control of 
M. musculinus in mice.
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